CYTK
Cytokinetics, Incorporated
NASDAQ · USHealthcareBiotechnology
$79.11-1.33%
Price as of Jul 20, 2026
CYTK financials
Cytokinetics, Incorporated financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $88.0M | $18.5M | $7.5M | $94.6M |
| Cost of revenue | $10.1M | $339.4M | $330.1M | $240.8M |
| Gross profit | $77.9M | -$320.9M | -$322.6M | -$146.2M |
| Operating expenses | $690.2M | $215.3M | $173.6M | $178.0M |
| Operating income | -$612.3M | -$536.2M | -$496.2M | -$324.2M |
| Net income | -$785.0M | -$589.5M | -$526.2M | -$389.0M |
| EBITDA | -$775.3M | -$493.5M | -$456.7M | -$329.4M |
| Basic EPS | $-6.54 | $-5.26 | $-5.45 | $-4.33 |
| Diluted EPS | $-6.54 | $-5.26 | $-5.45 | $-4.33 |
| Balance sheet | ||||
| Cash & equivalents | $122.5M | $94.9M | $113.0M | $65.6M |
| Total assets | $1.4B | $1.4B | $824.3M | $1.0B |
| Total liabilities | $2.1B | $1.5B | $1.2B | $1.1B |
| Stockholders’ equity | -$659.6M | -$135.4M | -$386.3M | -$107.9M |
| Total debt | $1.3B | $788.7M | $755.8M | $750.3M |
| Net debt | $1.2B | $693.8M | $642.7M | $684.7M |
| Cash flow | ||||
| Operating cash flow | -$510.0M | -$395.9M | -$414.3M | -$299.5M |
| Capital expenditure | -$24.8M | -$3.9M | -$1.4M | -$11.3M |
| Free cash flow | -$534.8M | -$399.8M | -$415.7M | -$310.9M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |